{"prompt": "['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'Section 4: Study Design Overview', 'Type of study: to be combined with other protocols for analysis to be combined', 'with other protocols for analysis to be combined with other protocols for analysis:', 'data to be analysed in this study have been collected in ZOSTER-006 (eTrack', '110390) and ZOSTER-022 (eTrack 113077).', 'Data collection: CRF/eCRF CRF/cCRF CRF/cCRF', 'Section 8.3.1: Check inclusion and exclusion criteria', 'Check all applicable inclusion and exclusion criteria as described in Sections 0 6.2', 'and 6.3, respectively, before encoding of subject data.', 'Checking of the eligibility criteria will be performed centrally. Sites will receive a', 'list of subjects for which data and QoL questionnaires should be encoded (see', 'Section 8.1).', 'Section 10.5.2 modified Total Vaccinated Cohort', '11-FEB-2019', '80', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'GlaxoSmithKline Biologicals SA', 'Vaccines R &D', 'Protocol Administrative Change 3', 'eTrack study number', '204878 (ZOSTER-064)', 'and Abbreviated Title', 'IND number', 'BB-IND-13857', 'Administrative change', 'Administrative Change 3', 'number:', 'Administrative change', '11 February 2019', 'date:', 'PPD', 'Co-ordinating author:', 'Scientific Writer, XPE Pharma &', ',', 'Science for GSK Biologicals', 'Rationale/background for changes:', 'The Japan Vaccine Company will no longer be in operation as of 01 April 2019.', 'Therefore, the reference to \"Japan Vaccine Co., Ltd.\" has been changed to \"GSK', 'Japan\"', 'Amended text has been included in bold italics and deleted text in strikethrough in', 'the following sections:', 'Added to authors:', 'PPD', 'Scientific Writer, XPE Pharma & Science for GSK Biologicals', ',', 'PPD', ',', 'Global Regulatory Affairs', 'On page 2 changed copyright date: C 2018-2019 GSK group of companies or its licensor.', 'On page 7 Signature page for Japan representative: GSK Japan JapanVaccine Co', 'representative name, function and title', \"Section 8.1 Subject Identification: Date of subject's consent\", '11-FEB-2019', '81', '70882527ffe6806e42bab9a20b06541da11028ce']\n\n###\n\n", "completion": "END"}